Daiichi Sankyo Company, Limited
4568
Rankning i aktier
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Aktiekurs
$18.01
Marknadsvärde
$32.77B
Förändring (1 dag)
0.14%
Förändring (1 år)
-30.22%
Land
JP
Handel Daiichi Sankyo Company, Limited (4568)
Kategori
Healthcare
Rörelsemarginal för Daiichi Sankyo Company, Limited (4568)
Rörelsemarginal per October 2026 TTM: 8.83%
Enligt de senaste finansiella rapporterna och aktiekursen för Daiichi Sankyo Company, Limited är företagets nuvarande rörelsemarginal (TTM) 8.83%. Vid slutet av 2025 var rörelsemarginalen 16.08%.
Historik för rörelsemarginal för Daiichi Sankyo Company, Limited från 2001 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 8.83% | -45.09% |
| 2025 | 16.08% | 39.83% |
| 2024 | 11.50% | 43.93% |
| 2023 | 7.99% | -42.85% |
| 2022 | 13.98% | 5.43% |
| 2021 | 13.26% | -53.10% |
| 2020 | 28.27% | 56.97% |
| 2019 | 18.01% | 13.34% |
| 2018 | 15.89% | -14.66% |
| 2017 | 18.62% | -29.58% |
| 2016 | 26.44% | 63.31% |
| 2015 | 16.19% | 21.64% |
| 2014 | 13.31% | 32.17% |
| 2013 | 10.07% | -3.73% |
| 2012 | 10.46% | -17.18% |
| 2011 | 12.63% | 25.92% |
| 2010 | 10.03% | -4.93% |
| 2009 | 10.55% | -40.80% |
| 2008 | 17.82% | 21.47% |
| 2007 | 14.67% | -12.21% |
| 2006 | 16.71% | 15.64% |
| 2005 | 14.45% | -9.80% |
| 2004 | 16.02% | 14.35% |
| 2003 | 14.01% | -4.63% |
| 2002 | 14.69% | -8.81% |
| 2001 | 16.11% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 49.72% | -94.37% |
US
|
|
| 25.70% | -97.09% |
US
|
|
| 29.32% | -96.68% |
US
|
|
| 16.65% | -98.11% |
US
|
|
| 31.92% | -96.39% |
CH
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.